Videos

The hematologist and oncologist from UCSF Helen Diller Family Comprehensive Cancer Center discussed the potential utility of natural killer cells in multiple myeloma.

The professor from National Taiwan University Hospital discussed the challenges of working with a rare disease.

The chief executive officer of Rocket Pharmaceuticals, Gaurav Shah, MD, discussed the company’s lead programs and future plans.

The professor from University of Texas MD Anderson Cancer Center discussed the real-world efficacy of the first CAR T therapy for the treatment of mantle cell lymphoma.

The hematological oncologist from University of Chicago Medicine discussed chimeric antigen receptor T cells therapy in non-Hodgkin lymphoma.

The director at Dana-Farber Cancer Institute discussed future efforts to prevent the development of multiple myeloma.

The professor from National Taiwan University Hospital discussed further research he would like to do with the gene therapy PTC-AADC.

The hematologist/oncologist from UCSF Helen Diller Family Comprehensive Cancer Center discussed the potential of vaccine-based therapies in multiple myeloma.

André Choulika, PhD, chief executive officer and cofounder, Cellectis, discussed the company’s expansion into gene therapies.

Doctors from University of Washington and Cleveland Clinic discussed targeting CD19 in CAR T-cell therapy for relapsed/refractory DLBCL.

The professor from National Taiwan University Hospital discussed the mechanism of gene therapy in AADC deficiency.

Jessica Baker Flechtner, PhD, chief scientific officer, Genocea, discussed the company’s focus on solid tumors and manufacturing cell therapies.

Josh Ludwig, global director, commercial operations, ScaleReady, discussed making cell and gene therapy widely practical and viable for patients with cancer.

André Choulika, PhD, chief executive officer and cofounder, Cellectis, discussed the company’s partnerships and science.

The hematologist from Moffitt Cancer Center discussed the promise of ALLO-715 in relapsed/refractory multiple myeloma.

The hematologist and medical oncologist discussed next steps with CAR T-cell therapy in penta-refractory multiple myeloma.

Jake Becraft, PhD, chief executive officer and cofounder, Strand Therapeutics, discussed the company’s future research and plans.

Rick Fair, president and chief executive officer, Bellicum Pharmaceuticals, discussed the company’s GoCAR, iMC, and caspaCIDe technologies.

The professor from National Taiwan University Hospital discussed 3 studies of PTC-AADC for AADC deficiency.

The assistant professor of medicine from Medical College of Wisconsin discussed the potential impact of CAR T-cell therapy on the efficacy of COVID-19 vaccinations.

The professor of medicine at Washington University School of Medicine in St. Louis discussed the potential utility of frontline CAR T-cell therapy in mantle cell lymphoma.

The director of the Powell Gene Therapy Center at the University of Florida discussed improving access to gene therapies for patients with rare diseases worldwide.

The chief of oncology and hematology at University of Nebraska Medical Center discussed the use of CAR T-cell therapy in non-Hodgkin lymphoma.

The hematology and medical oncologist at Moffitt Cancer Center discussed results from the phase 1b/2 CARTITUDE-1 trial of cita-cel in R/R MM.

The associate professor from Harold C. Simmons Comprehensive Cancer Center discussed the methodology of the phase 2 KarMMa trial.

The hematologist from Moffitt Cancer Center discussed the survival benefit of ide-cel in the phase 2 KarMMa trial.

Jessica Baker Flechtner, PhD, chief scientific officer, Genocea, discussed the ATLAS platform and the TiTAN trial.

André Choulika, PhD, chief executive officer and cofounder, Cellectis, discussed therapies the company is developing.